List of Excipients in Branded Drug ALEVE HEADACHE PAIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare LLC	ALEVE HEADACHE PAIN	naproxen sodium	0280-0041	CELLULOSE, MICROCRYSTALLINE
Bayer HealthCare LLC	ALEVE HEADACHE PAIN	naproxen sodium	0280-0041	FD&C BLUE NO. 2
Bayer HealthCare LLC	ALEVE HEADACHE PAIN	naproxen sodium	0280-0041	HYPROMELLOSES
Bayer HealthCare LLC	ALEVE HEADACHE PAIN	naproxen sodium	0280-0041	MAGNESIUM STEARATE
Bayer HealthCare LLC	ALEVE HEADACHE PAIN	naproxen sodium	0280-0041	POLYETHYLENE GLYCOL
Bayer HealthCare LLC	ALEVE HEADACHE PAIN	naproxen sodium	0280-0041	POVIDONE
Bayer HealthCare LLC	ALEVE HEADACHE PAIN	naproxen sodium	0280-0041	TALC

Aleve Headache Pain Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Aleve Headache Pain is an over-the-counter combination product containing naproxen sodium 220 mg and caffeine 60 mg per caplet. Its commercial opportunity is based on rapid-release performance, differentiated headache positioning, packaging, channel expansion and private-label manufacturing rather than conventional prescription patent exclusivity. The strongest excipient strategy is a robust immediate-release tablet platform that supports fast disintegration, caffeine uniformity, chemical stability and low-cost high-volume production.

What is Aleve Headache Pain and how is it regulated?

Aleve Headache Pain combines an NSAID analgesic with caffeine:

Attribute	Product profile
Brand	Aleve Headache Pain
Active ingredients	Naproxen sodium 220 mg; caffeine 60 mg
Dosage form	Oral immediate-release caplet
Therapeutic category	OTC analgesic and headache-relief product
Primary indication	Temporary relief of minor aches and pains associated with headache
Manufacturer/brand owner	Bayer Consumer Health, subject to market-specific commercialization arrangements
US regulatory status	OTC marketed product with FDA Drug Facts labeling
Biologic status	Not applicable
Biosimilar risk	None
Generic risk	OTC private-label and store-brand substitution

Naproxen sodium is an FDA-recognized OTC analgesic active ingredient. The naproxen sodium component is subject to the FDA’s OTC internal analgesic framework, while the naproxen-caffeine combination and its labeling must be assessed through the applicable FDA regulatory pathway and product-specific records.[1,2]

The product is not a biologic and does not have biosimilar exposure. Competition comes from other NSAIDs, acetaminophen-caffeine products, migraine products and store-brand equivalents.

What excipients are used in Aleve Headache Pain?

Public product labeling identifies a conventional compressed-tablet excipient system built around microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate and film-coating materials.[2] The exact commercial composition, supplier grades and manufacturing process should be treated as product-specific technical information.

The likely functional architecture is:

Excipient function	Strategic role
Microcrystalline cellulose	Diluent, tablet binding and compactability
Croscarmellose sodium	Superdisintegrant for rapid tablet breakup
Povidone	Binder and granulation aid
Magnesium stearate	Lubricant for compression and ejection
Hypromellose or similar film former	Tablet coating and moisture protection
Talc or mineral processing aid	Coating flow and anti-tacking
Titanium dioxide or approved colorant	Appearance and brand identification
Surfactant, where used	Wetting and dissolution support

The principal formulation challenge is balancing two active ingredients with different dose levels and physical properties. Naproxen sodium represents most of the tablet mass, while caffeine is present at a lower dose and must remain uniformly distributed throughout blending, granulation and compression.

What excipient risks affect product performance?

The major technical risks are:

1. Caffeine segregation. Caffeine particle size, density and flow can differ from naproxen sodium and the filler system. Segregation can create content-uniformity failures.
2. Over-lubrication. Excess magnesium stearate or prolonged blending can reduce tablet wetting and slow dissolution.
3. Moisture exposure. Moisture can affect flow, tablet hardness, coating integrity and long-term stability.
4. Compression variability. Excessive hardness may delay disintegration, while insufficient hardness can produce friability, chipping and packaging losses.
5. Coating interactions. Film coating improves appearance and handling but can delay wetting if applied too heavily or formulated with excessive hydrophobic material.
6. Taste and mouthfeel. Caffeine and naproxen sodium can create a bitter or alkaline taste if the tablet is chewed or damaged.

How should the excipient strategy be optimized?

The preferred development strategy is an immediate-release, dry-blend or high-shear wet-granulation platform selected through comparative manufacturability testing.

Immediate-release performance

Croscarmellose sodium is the primary disintegration lever. Development should evaluate:

• Intratablet concentration and distribution
• Intragranular versus extragranular placement
• Tablet hardness and tensile strength
• Water uptake and disintegration time
• Dissolution in multiple pH conditions
• Performance after accelerated stability storage

A formulation that meets dissolution targets only at low compression force may be commercially weak. The preferred formulation should maintain release performance across normal press-speed, hardness and lubricant variations.

Caffeine content uniformity

Caffeine should be controlled through particle engineering and blend design rather than relying only on final-product testing. Commercial options include:

• Narrow particle-size caffeine
• Pre-blended caffeine concentrate
• Coated or granulated caffeine
• Geometric dilution before full-batch blending
• Controlled-order addition of powders
• Near-infrared or other process analytical technology for blend monitoring

A pre-granulated caffeine intermediate can reduce segregation and dusting, although it adds process steps and may increase cost.

Naproxen sodium stability

Naproxen sodium is relatively suitable for solid oral dosage forms, but the formulation must control moisture, excipient impurities and coating permeability. The development program should assess:

• Water activity
• Residual solvent and moisture levels
• Oxidative and photolytic stress
• Compatibility between naproxen sodium, caffeine and excipients
• Container-closure protection
• Dissolution after storage
• Tablet appearance and mechanical strength

Low-moisture excipient grades and a protective film coat can extend manufacturing robustness. Desiccant packaging may be useful for humid markets, but it raises packaging cost and consumer-use complexity.

Manufacturing cost

For a high-volume OTC product, the best formulation is not necessarily the one with the fastest laboratory dissolution. It is the one that provides acceptable dissolution while minimizing:

• Granulation energy
• Number of processing stages
• Coating time
• Tablet weight
• Press stoppages
• Dust generation
• Cleaning burden
• Rejection rates
• Packaging losses

A direct-compression formulation would offer the lowest process complexity if powder flow, content uniformity and tablet strength are adequate. Wet granulation may provide better control of caffeine distribution and compression but would increase capital, validation and operating costs.

What formulations are commercially protected or differentiated?

The core caplet formulation is unlikely to provide meaningful long-term exclusivity by itself unless protected by a valid patent covering a specific composition, manufacturing process, release profile or use. The main commercial formulation opportunities are:

Rapid-release caplet

A conventional film-coated caplet remains the lowest-risk platform. Differentiation can come from tighter dissolution specifications, smaller tablet size, improved swallowability or faster disintegration.

Softgel or liquid-filled capsule

A liquid-filled capsule could improve swallowability and create a premium format. It would require careful compatibility work because naproxen sodium and caffeine would need to remain chemically and physically stable in the selected vehicle. The format may also create higher manufacturing and packaging costs.

Fast-dissolving or orally disintegrating product

An orally disintegrating version could target consumers who have difficulty swallowing tablets. The bitter taste of caffeine and naproxen sodium would make taste masking a central development issue. This format would require a different excipient system, including stronger flavor, sweetener and saliva-triggered disintegration controls.

Powder or sachet

A drinkable powder could support rapid administration and portability. It would require attention to caffeine taste, naproxen sodium solubility, dose uniformity, moisture protection and consumer preparation instructions. Sachets create opportunities for travel, convenience and e-commerce channels.

Dual-layer tablet

A bilayer design could separate the two actives or create a fast-release caffeine layer. This approach may improve formulation control but adds equipment and process complexity. It is most commercially defensible when linked to a demonstrable release or stability advantage.

Lower-sodium or alternative salt strategy

Replacing naproxen sodium with another naproxen form would change the active ingredient specification and require regulatory and bioequivalence analysis. It may create a technical platform but would not automatically preserve the Aleve brand’s existing regulatory position.

When does Aleve Headache Pain lose exclusivity?

Aleve Headache Pain does not depend on a conventional prescription-drug patent or FDA new chemical entity exclusivity period. The principal commercial barriers are:

• Brand recognition
• Trademark rights
• FDA-compliant labeling
• Product quality history
• Retail distribution
• Manufacturing scale
• Advertising and consumer trust
• Packaging and trade dress

The active ingredients are established OTC substances. Competitors can develop store-brand naproxen-caffeine products if they satisfy applicable FDA requirements and avoid infringing trademarks, patents or protected labeling.

What is the Orange Book status of Aleve Headache Pain?

Aleve Headache Pain is an OTC product rather than a standard prescription NDA product used for Orange Book patent-certification competition. As a result, the commercial analysis should not rely on an Orange Book expiration date in the same manner as a prescription drug.

The Orange Book is designed primarily for approved drug products with therapeutic-equivalence listings and patent information submitted under the Hatch-Waxman framework.[3] OTC competition generally occurs through the monograph system, an approved OTC application where applicable, or an alternative regulatory route.

Are there Paragraph IV challenges?

A conventional Paragraph IV challenge is not the expected competitive mechanism for this product. Paragraph IV certifications apply to patents listed for eligible reference drugs in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations. OTC store-brand entrants instead face regulatory, labeling, quality, trademark and potential formulation-patent issues.

What patent litigation affects Aleve Headache Pain?

No major public patent-litigation pathway is inherent in the product’s OTC status. The relevant legal risks would arise from:

• A formulation patent covering a specific naproxen-caffeine composition
• A process patent covering granulation, coating or manufacturing
• A delivery-system patent covering a softgel, sachet or fast-dissolving format
• A method-of-use patent covering a narrowly defined headache regimen
• Trademark or trade-dress claims involving the Aleve brand
• Contractual restrictions involving a contract manufacturer or technology licensor

Method-of-use patents would have limited commercial leverage for a broadly labeled OTC headache product unless the claimed method is narrow, clinically supported and reflected in enforceable labeling. Manufacturing patents may be more practical where they cover a distinctive granulation, coating or content-uniformity process.

Which companies are challenging Aleve Headache Pain?

The principal competitive threats are private-label retailers, OTC manufacturers and branded analgesic companies rather than named Paragraph IV challengers.

Competitor category	Examples of competitive products or companies
Naproxen sodium generics	Store-brand and pharmacy-brand naproxen sodium products
Ibuprofen brands	Advil and private-label ibuprofen
Acetaminophen-caffeine products	Excedrin and store-brand equivalents
Migraine-specific products	Branded and generic migraine treatments
Retailers	Mass merchants, drugstores and e-commerce private labels
Contract manufacturers	OTC manufacturers producing retailer-branded analgesics

The most direct substitution risk comes from a private-label product combining naproxen sodium and caffeine. A retailer can compete on price if it matches tablet performance, labeling and packaging quality.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can capture value through performance, regulatory support and supply-chain reliability.

High-value excipient opportunities

• Direct-compression microcrystalline cellulose with consistent flow
• Low-moisture grades for stability-sensitive tablets
• Co-processed excipients that reduce granulation requirements
• Fast-acting superdisintegrant systems
• Low-level lubricant systems that preserve dissolution
• Taste-masking polymers for powders and orally disintegrating formats
• Film coatings with improved moisture protection
• Caffeine premixes or granulated caffeine intermediates
• Color systems that improve brand differentiation
• Near-infrared calibration standards and process-control support

A supplier with a qualified, dual-sourceable excipient can have greater commercial value than a supplier offering a marginally better laboratory result but creating regulatory or continuity risk.

Licensing opportunities

Potential licensing targets include:

• Rapid-release delivery technologies
• Caffeine taste-masking systems
• Low-moisture tablet platforms
• Co-processed direct-compression excipients
• Fast-dissolving oral dosage systems
• Unit-dose sachet technologies
• Child-resistant or senior-friendly packaging
• Continuous manufacturing and real-time blend monitoring

A formulation license is most defensible when it produces a measurable advantage, such as faster disintegration, lower tablet weight, longer shelf life or reduced manufacturing cost.

How does Aleve Headache Pain compare with competing analgesics?

Product type	Active ingredient profile	Main advantage	Main excipient challenge
Aleve Headache Pain	Naproxen sodium plus caffeine	NSAID analgesia with caffeine combination	Content uniformity and rapid release
Standard naproxen sodium	Naproxen sodium	Low-cost established analgesic	Limited differentiation
Ibuprofen products	Ibuprofen	Broad OTC availability and multiple dosage forms	Dose loading and tablet size
Acetaminophen-caffeine products	Acetaminophen plus caffeine	Strong headache brand recognition	Taste, liver-safety labeling and caffeine positioning
Migraine products	Combination analgesic or migraine-specific active	Condition-specific marketing	More complex labeling and positioning

Aleve Headache Pain can command a premium over standard naproxen sodium if consumers recognize a meaningful headache benefit. The premium is vulnerable when private-label products offer the same active ingredients and similar packaging claims.

What generic launch risks exist?

Generic and private-label launch risk is high because:

• The active ingredients are established.
• The product is orally administered.
• The dosage form is technically conventional.
• Consumer demand is measurable through existing analgesic categories.
• Retailers can use private-label shelf space.
• Brand switching is common in OTC analgesics.
• Manufacturing barriers are manageable for qualified OTC producers.

The strongest barriers are regulatory execution, supply consistency, retail placement and brand economics. A competitor does not need to reproduce every excipient exactly. It generally needs to deliver compliant quality, acceptable dissolution, stable shelf life and commercially credible packaging.

What is the geographic coverage and manufacturing opportunity?

The commercial platform is most transferable to markets where naproxen and caffeine combinations are permitted or can be approved under local OTC or nonprescription pathways. Geographic expansion requires country-specific review of:

• Permitted active-ingredient combinations
• Maximum daily doses
• Caffeine warnings
• NSAID contraindications
• Pregnancy and cardiovascular labeling
• Excipient acceptability
• Language and packaging rules
• Stability zones
• Pharmacovigilance requirements

Manufacturing can be performed through large-scale tablet plants with high-speed compression and film coating. The preferred supply model is dual sourcing for naproxen sodium, caffeine, critical disintegrant and coating materials. Qualification of alternate suppliers should preserve particle-size distribution, bulk density, moisture and compaction behavior.

Key Takeaways

• Aleve Headache Pain contains naproxen sodium 220 mg and caffeine 60 mg per caplet.
• Its core dosage form is a conventional immediate-release film-coated tablet.
• The highest-value excipient priorities are caffeine uniformity, rapid disintegration, moisture control and low-cost compression.
• Croscarmellose sodium, microcrystalline cellulose, povidone and magnesium stearate form the likely core functional system.
• The product does not have the typical prescription-drug patent-expiration profile.
• Paragraph IV litigation is not the expected competitive pathway.
• Private-label naproxen-caffeine products represent the most direct generic threat.
• Commercial opportunities include rapid-release caplets, softgels, sachets, orally disintegrating products and excipient-enabled manufacturing improvements.
• The strongest licensing assets are technologies that reduce cost or produce a measurable release, stability or taste advantage.
• Geographic expansion depends on local approval of the naproxen-caffeine combination and country-specific NSAID labeling.

FAQs

Can a private-label company copy the Aleve Headache Pain excipients?

It can develop a product with the same active ingredients and a different excipient system, subject to applicable FDA requirements, quality standards, labeling rules, trademarks and enforceable patents.

Is caffeine an excipient in Aleve Headache Pain?

No. Caffeine is an active ingredient in the product. Excipients are the inactive formulation materials used for binding, filling, disintegration, lubrication, coating and stability.

What is the best dosage form for a lower-cost competitor?

A conventional immediate-release film-coated caplet is likely to offer the best balance of cost, manufacturing throughput, stability and regulatory simplicity.

Can a fast-dissolving version obtain patent protection?

Potentially, if the product has a novel and non-obvious composition, release profile, manufacturing process or stability result. A generic fast-dissolving formulation would not automatically receive exclusivity.

Does Aleve Headache Pain have biosimilar competition?

No. Aleve Headache Pain is a small-molecule OTC drug product, so its competition comes from generics, private-label analgesics and other branded headache products.

References

1. U.S. Food and Drug Administration. (2024). Over-the-counter monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. FDA.

2. DailyMed. (n.d.). Aleve Headache Pain: Naproxen sodium and caffeine tablet, film coated. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.